Preventing cisplatin-induced ototoxicity in pediatrics – Join us for a free webinar on March 5 to learn how to reduce risk and improve patient outcomes

On March 5 at 2 pm ET, Med Safety Board (MSB), a subsidiary of the Institute for Safe Medication Practices (ISMP), will host an educational program in which expert faculty will review therapy considerations for reducing the risk of cisplatin-induced ototoxicity in pediatric, adolescent, and young adult patients. 

Cisplatin is a commonly used chemotherapeutic agent for the treatment of certain childhood cancers, including germ cell tumors, hepatoblastoma, medulloblastoma, neuroblastoma, and osteosarcoma. However, as a known ototoxic agent, patients can risk permanent, bilateral hearing loss due to cisplatin use, with pediatric patients, especially younger children, at an increased risk for severe ototoxic effects. Hearing loss in this patient population can lead to delays in speech and language development and can also have a detrimental psychosocial and quality-of-life impact on pediatric, adolescent, and young adult patients receiving cisplatin therapy. 

This educational program will discuss the incidence and mechanism of cisplatin-induced ototoxicity. Expert faculty will share safety and efficacy data of sodium thiosulfate injection in the prevention of cisplatin-induced ototoxicity. The safety implications of select inactive ingredients in pharmaceutical products in the pediatric population will also be addressed. 

Download Handouts

Learning Objectives:  

Following this educational program, participants will be able to: 

1. Understand the incidence and mechanism of cisplatin-induced ototoxicity in children  
2. Discuss the mechanism of action and safety and efficacy data of sodium thiosulfate in the prevention of cisplatin-induced ototoxicity 
3. Describe the safety impact of select inactive ingredients in pharmaceutical products in pediatric patients  

Speakers:

Rita K. Jew, PharmD, MBA, BCPPS, FASHP President, ISMP

Noah C. Federman, MD Nancy and Jonathan Glaser Family Endowed Chair for Pediatric Sarcomas Health Sciences Professor, Pediatrics and Orthopaedic Surgery  Medical Director, CTSI Clinical and Translational Research Center Director, UCLA CIRM Alpha Stem Cell Clinic Director, UCLA Pediatric Bone and Soft Tissue Sarcoma Program, UCLA Health; Jonsson Comprehensive Cancer Center; Clinical and Translational Science Institute; Mattel Children’s Hospital and David Geffen School of Medicine

Sponsorship:
This educational program is sponsored by Fennec Pharmaceuticals